, Volume 34, Issue 7, pp 978-981,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 02 Mar 2007

The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?

This is an excerpt from the content

In this issue of the European Journal of Nuclear Medicine and Molecular Imaging, the article by Antunes et al., entitled “Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?”, provides another example of the high potential of the 68Ge/68Ga generator for PET applications in nuclear medicine. The use of 68Ge/68Ga generators in nuclear medicine is very attractive for several reasons:

  1. The 270-day half-life of the parent 68Ge allows use of the generator for a long period, potentially up to 1 year or even longer.

  2. The 68-min half-life of 68Ga matches the pharmacokinetics of many peptides and other small molecules owing to rapid diffusion, localisation at the target and fast blood clearance.

  3. The PET radionuclide68Ga is continuously available at a reasonable cost from a 68Ge/68Ga generator, including for centres without a cyclotron.

  4. Besides the DOTA analogues of somatostatin [15], DOTA-derivatised analogues of several other ...

This editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-006-0317-x.